Experimental shot aims to reverse HPV-Linked cervical precancer
NCT ID NCT07712692
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests an experimental biologic, NWRD09, in women aged 18 to 65 with HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL), a precancerous condition. Participants receive four intramuscular injections over 12 weeks. The main goal is to see if the treatment can shrink or eliminate these abnormal cells by the 24-week mark, offering a potential alternative to surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental biologic called NWRD09
- What this could lead to
- If successful, this could offer a non-surgical treatment option for women with HPV16-related cervical precancer, potentially preventing progression to cancer.
- What could go wrong
- This is an early Phase 2 trial with a small sample size, so results may not confirm efficacy or safety. The treatment may not cause lesion regression, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Contact Email: •••••@•••••
Contact
-
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dalian Maternal and Child Health Hospital
Dalian, China
Contact
Contact
-
Gansu Provincial Maternity and Child-care Hospital / Gansu Provincial central Hospital
Lanzhou, Gansu, China
Contact
Contact
-
Nanjing Maternity and Child Health Care Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Qilu Hospital of Shandong University
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanxi Maternal and Child Health Hospital
Taiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact Phone: •••-•••-••••
Contact
-
The First Hospital Affiliated to AMU (SOUTHWEST HOSPITAL)
Chongqing, Chongqing Municipality, China
Contact
Contact
-
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Contact
-
The Second Hospital of Jilin University
Changchun, Jilin, China
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.